Equities Analysts Offer Predictions for Achillion Pharmaceuticals, Inc.’s FY2017 Earnings (ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – William Blair upped their FY2017 earnings estimates for shares of Achillion Pharmaceuticals in a research report issued to clients and investors on Wednesday. William Blair analyst Y. Xu now expects that the biopharmaceutical company will earn ($0.61) per share for the year, up from their prior forecast of ($0.70). William Blair also issued estimates for Achillion Pharmaceuticals’ Q4 2017 earnings at ($0.16) EPS, Q1 2018 earnings at ($0.17) EPS, Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.21) EPS, Q4 2018 earnings at ($0.22) EPS, FY2018 earnings at ($0.79) EPS and FY2019 earnings at ($1.00) EPS.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter last year, the firm earned ($0.15) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Achillion Pharmaceuticals, Inc.’s FY2017 Earnings (ACHN)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/06/equities-analysts-offer-predictions-for-achillion-pharmaceuticals-inc-s-fy2017-earnings-achn.html.

A number of other equities analysts have also commented on ACHN. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Monday. Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Robert W. Baird lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research report on Thursday, August 10th. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Finally, Chardan Capital dropped their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.33.

Shares of Achillion Pharmaceuticals (ACHN) opened at $4.05 on Monday. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $5.66.

Large investors have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. increased its position in Achillion Pharmaceuticals by 3.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 800 shares during the period. Schwab Charles Investment Management Inc. increased its position in Achillion Pharmaceuticals by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after acquiring an additional 2,850 shares during the period. Bank of Montreal Can increased its position in Achillion Pharmaceuticals by 6.4% during the second quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 3,410 shares during the period. Wells Fargo & Company MN increased its position in Achillion Pharmaceuticals by 1.8% during the second quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 3,827 shares during the period. Finally, SG Americas Securities LLC increased its position in Achillion Pharmaceuticals by 18.6% during the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 4,144 shares during the period. 74.62% of the stock is currently owned by institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

What are top analysts saying about Achillion Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achillion Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit